Page last updated: 2024-09-05

sorafenib and camptothecin

sorafenib has been researched along with camptothecin in 21 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(camptothecin)
Trials
(camptothecin)
Recent Studies (post-2010) (camptothecin)
6,5207305,25113,0022,2295,391

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)camptothecin (IC50)
Histone deacetylase 3Homo sapiens (human)0.05
Multidrug resistance-associated protein 4Homo sapiens (human)7.4
DNA topoisomerase 1Homo sapiens (human)1.9799
Somatostatin receptor type 1Homo sapiens (human)0.0022
Somatostatin receptor type 2Homo sapiens (human)0.0022
Somatostatin receptor type 4Homo sapiens (human)0.0022
Somatostatin receptor type 3Homo sapiens (human)0.0022
Somatostatin receptor type 5Homo sapiens (human)0.0022
5-hydroxytryptamine receptor 2BHomo sapiens (human)0.97
Histone deacetylase 4Homo sapiens (human)0.05
Histone deacetylase 1Homo sapiens (human)0.05
Histone deacetylase 7Homo sapiens (human)0.05
Histone deacetylase 2Homo sapiens (human)0.05
Polyamine deacetylase HDAC10Homo sapiens (human)0.05
Histone deacetylase 11 Homo sapiens (human)0.05
Histone deacetylase 8Homo sapiens (human)0.05
Histone deacetylase 6Homo sapiens (human)0.05
Histone deacetylase 9Homo sapiens (human)0.05
Histone deacetylase 5Homo sapiens (human)0.05

Research

Studies (21)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (14.29)29.6817
2010's14 (66.67)24.3611
2020's4 (19.05)2.80

Authors

AuthorsStudies
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ1
Chen, Y; Han, J; Liu, T; Song, Y; Wang, M; Xu, H; Yang, C; Zhang, L; Zheng, C; Zhu, J1
Liu, Y; Xu, Z; Zhao, SJ1
Abdelhamid, D; Abuo-Rahma, GEA; Badr, M; Hassan, A; Hassan, HA1
Deng, X; Jiang, W; Li, Y; Liu, L; Luo, T; Wang, Z; Xie, L; Zhang, X1
Baas, F; Brendel, E; Buss, P; Mersmann, S; Mross, K; Reil, M; Schwartz, B; Steinbild, S; Voliotis, D1
Baas, F; Brendel, E; Christensen, O; Gmehling, D; Mross, K; Radtke, M; Steinbild, S; Unger, C; Voliotis, D1
Pappo, A; Paulino, AC1
Abdulghani, J; Allen, JE; Dicker, DT; Dolloff, NG; El-Deiry, WS; Gallant, JN; Hong, B; Katz, SI; Navaraj, A; Smith, CD; Wang, W1
Arcaroli, J; Azad, N; Carducci, MA; Dasari, A; Diaz, LA; Donehower, RC; Hidalgo, M; Laheru, DA; McManus, M; Messersmith, WA; Quackenbush, K; Rudek, MA; Taylor, GE; Wright, JJ; Zhao, M1
Assenat, E; Causse, A; Del Rio, M; Evrard, A; Gongora, C; Jarlier, M; Leconet, W; Martineau, P; Mazard, T; Robert, B; Simony, J; Torro, A; Vezzio-Vie, N; Ychou, M1
Adenis, A; Assenat, E; Bennouna, J; Bibeau, F; Boissière, F; Bouché, O; Conroy, T; Crapez, E; Desseigne, F; Francois, E; Galais, MP; Laurent-Puig, P; Mazard, T; Poujol, S; Samalin, E; Seitz, JF; Taieb, J; Thézenas, S; Ychou, M1
Afonso, R; Angeles, C; Campos, JM; García-Alfonso, P; Grande, E; Jorge, M; Martínez, V; Montagut, C; Polo, E; Reina, JJ1
Borad, MJ; Erlichman, C; Grothey, A; Hubbard, JM; Johnson, E; Kim, G; Lensing, J; Puttabasavaiah, S; Qin, R; Wright, J1
Jian, C; Pei-hua, L; Xiao-chun, Y; Xu, L; Yuan-run, Z1
Durmus, S; Schinkel, AH; van Hoppe, S1
Hu, Y; Lin, A; Ma, C; Niu, Y; Shi, L; Su, Y; Zhang, C; Zhou, L; Zhu, X1
Goto, H; Goto, S; Hamanoue, S; Iwasaki, F; Keino, D; Kitagawa, N; Miyagawa, N; Miyagi, Y; Sarashina, T; Sekiguchi, H; Shiomi, M; Sugiyama, M; Tanaka, Y; Yokosuka, T1
Alonso, V; Asensio, E; Camps, J; Castells, A; Codony-Servat, J; Cuatrecasas, M; Escudero, P; Feliu, J; Fernández-Martos, C; Gaba, L; Gallego, J; García-Albéniz, X; Horndler, C; Jares, P; Marín-Aguilera, M; Martín-Richard, M; Martínez-Balibrea, E; Martínez-Cardús, A; Maurel, J; Méndez, JC; Méndez, M; Montironi, C; Prat, A; Reig, O; Rojo, F; Rosell, R; Rubini, M; Salud, A; Victoria, I1
Chang, S; Chen, F; Li, G; Li, X; Liu, Q; Meng, F; Sun, L; Wang, H; Zhang, J1
Ali, SA; Atya, HB; Elkateb, AS; Nofal, S1

Reviews

3 review(s) available for sorafenib and camptothecin

ArticleYear
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
    European journal of medicinal chemistry, 2019, Dec-01, Volume: 183

    Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles

2019
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
    Angiogenesis, 2014, Volume: 17, Issue:4

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Genes, ras; Humans; Imidazoles; Indazoles; Indoles; Irinotecan; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2014
The impact of Organic Anion-Transporting Polypeptides (OATPs) on disposition and toxicity of antitumor drugs: Insights from knockout and humanized mice.
    Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2016, Volume: 27

    Topics: Animals; Antineoplastic Agents; Camptothecin; Doxorubicin; Drug Interactions; Gene Expression; Hepatocytes; Humans; Inactivation, Metabolic; Irinotecan; Liver; Liver-Specific Organic Anion Transporter 1; Methotrexate; Mice; Mice, Transgenic; Neoplasms; Niacinamide; Organic Cation Transport Proteins; Phenylurea Compounds; Platinum Compounds; Sorafenib; Taxoids

2016

Trials

5 trial(s) available for sorafenib and camptothecin

ArticleYear
Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors.
    International journal of clinical pharmacology and therapeutics, 2003, Volume: 41, Issue:12

    Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Benzenesulfonates; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Humans; Irinotecan; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib

2003
Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib.
    European journal of cancer (Oxford, England : 1990), 2007, Volume: 43, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Microsomes, Liver; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2007
Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer.
    Investigational new drugs, 2013, Volume: 31, Issue:2

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Tissue Distribution

2013
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.
    British journal of cancer, 2014, Mar-04, Volume: 110, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Sorafenib

2014
Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies.
    Investigational new drugs, 2016, Volume: 34, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2016

Other Studies

13 other study(ies) available for sorafenib and camptothecin

ArticleYear
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics

2010
Structure-based optimization leads to the discovery of NSC765844, a highly potent, less toxic and orally efficacious dual PI3K/mTOR inhibitor.
    European journal of medicinal chemistry, 2016, Oct-21, Volume: 122

    Topics: Administration, Oral; Amino Acid Sequence; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Enzyme Inhibitors; Humans; Male; Models, Molecular; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Conformation; Rats; Signal Transduction; Structure-Activity Relationship; Sulfonamides; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2016
Novel 4-(piperazin-1-yl)quinolin-2(1H)-one bearing thiazoles with antiproliferative activity through VEGFR-2-TK inhibition.
    Bioorganic & medicinal chemistry, 2021, 06-15, Volume: 40

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Structure-Activity Relationship; Thiazoles; Vascular Endothelial Growth Factor Receptor-2

2021
Design, synthesis and biological evaluation of 3-arylisoquinoline derivatives as topoisomerase I and II dual inhibitors for the therapy of liver cancer.
    European journal of medicinal chemistry, 2022, Jul-05, Volume: 237

    Topics: Alkaloids; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Design; Humans; Isoquinolines; Liver Neoplasms; Molecular Docking Simulation; Phosphatidylinositol 3-Kinases; Structure-Activity Relationship; Topoisomerase II Inhibitors

2022
Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk?
    Pediatric blood & cancer, 2009, Dec-15, Volume: 53, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Camptothecin; Child; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Dactinomycin; Etoposide; Fatal Outcome; Female; Foot; Groin; Humans; Ifosfamide; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Lymphatic System; Male; Niacinamide; Phenylurea Compounds; Pyridines; Radiotherapy, Adjuvant; Radiotherapy, High-Energy; Rhabdomyosarcoma, Alveolar; Salvage Therapy; Soft Tissue Neoplasms; Sorafenib; Temozolomide; Thigh; Vincristine

2009
Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents.
    Cancer biology & therapy, 2011, Aug-01, Volume: 12, Issue:3

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Camptothecin; Carcinoma, Hepatocellular; Cell Death; Cell Nucleus; Cytoplasm; Deoxycytidine; Doxorubicin; Drug Synergism; Etoposide; Female; Fluorouracil; Gemcitabine; Genes, p53; Humans; Irinotecan; Liver Neoplasms; Mice; Microtubule-Associated Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Quinacrine; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Small Interfering; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2011
Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:10

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Irinotecan; Mice; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Sorafenib; Xenograft Model Antitumor Assays

2013
[Anticancer effect of SN-38 combined with sorafenib on hepatocellular carcinoma in vitro and its mechanism].
    Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2015, Volume: 44, Issue:5

    Topics: Apoptosis; Camptothecin; Carcinoma, Hepatocellular; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Histones; Humans; Irinotecan; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Poly(ADP-ribose) Polymerases; Sorafenib; Tumor Suppressor Protein p53

2015
Matrix Metalloproteinase Responsive Nanoparticles for Synergistic Treatment of Colorectal Cancer via Simultaneous Anti-Angiogenesis and Chemotherapy.
    Bioconjugate chemistry, 2016, Dec-21, Volume: 27, Issue:12

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Liberation; HT29 Cells; Humans; Male; Matrix Metalloproteinase 2; Mice, Inbred BALB C; Nanoparticles; Niacinamide; Phenylurea Compounds; Photoacoustic Techniques; Rats, Sprague-Dawley; Sorafenib; Tissue Distribution; Tumor Microenvironment; Xenograft Model Antitumor Assays

2016
The Collagen Gel Droplet-embedded Culture Drug Sensitivity Test in Relapsed Hepatoblastoma.
    Journal of pediatric hematology/oncology, 2017, Volume: 39, Issue:5

    Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Child; Child, Preschool; Collagen; Drug Screening Assays, Antitumor; Drug Synergism; Female; Hepatoblastoma; Humans; Indoles; Infant; Inhibitory Concentration 50; Irinotecan; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Recurrence; Sorafenib; Sunitinib

2017
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.
    British journal of cancer, 2017, Dec-05, Volume: 117, Issue:12

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cell Nucleus; Cell Survival; Cetuximab; Colorectal Neoplasms; Curcumin; Dasatinib; Drug Resistance, Neoplasm; Fatty Acids, Unsaturated; Female; Fluorouracil; Gene Silencing; HCT116 Cells; HT29 Cells; Humans; Leucovorin; Male; Middle Aged; Molecular Chaperones; Molecular Targeted Therapy; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Phenylurea Compounds; Protein Inhibitors of Activated STAT; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction; Sorafenib

2017
Camptothecin improves sorafenib sensitivity by inhibiting Nrf2‑ARE pathway in hepatocellular carcinoma.
    Oncology reports, 2023, Volume: 49, Issue:3

    Topics: Animals; Camptothecin; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Liver Neoplasms; Mice; NAD; NF-E2-Related Factor 2; Oxidoreductases; Quinones; Rabbits; Sorafenib

2023
Camptothecin Sensitizes Hepatocellular Carcinoma Cells to Sorafenib- Induced Ferroptosis Via Suppression of Nrf2.
    Inflammation, 2023, Volume: 46, Issue:4

    Topics: Camptothecin; Carcinoma, Hepatocellular; Cell Line, Tumor; Ferroptosis; Humans; Iron; Kelch-Like ECH-Associated Protein 1; Liver Neoplasms; NF-E2-Related Factor 2; Sorafenib

2023